Schonfeld Strategic Advisors LLC
Position in RLAY — Relay Therapeutics, Inc.
CIK 1665241
NEW YORK, NY
Position in RLAY
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$715,206
+$191,930 QoQ
Shares Held
71,880
+16.2% QoQ
Ownership
0.033%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2020
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RLAY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Schonfeld Strategic Advisors LLC holds $420,669,608 across 133 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INBX |
Inhibrx Biosciences, Inc.
|
697,586 | $66,096,273 | |
| 2 | AGIO |
Agios Pharmaceuticals, Inc.
|
520,083 | $19,300,280 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
77,272 | $18,620,233 | |
| 4 | VRDN |
Viridian Therapeutics, Inc.\DE
|
793,508 | $14,576,741 | |
| 5 | MBX |
MBX Biosciences, Inc.
|
248,670 | $13,726,584 | |
| 6 | XENE |
Xenon Pharmaceuticals Inc.
|
227,330 | $13,721,638 | |
| 7 | PTCT |
Ptc Therapeutics, Inc.
|
147,425 | $12,025,457 | |
| 8 | INSM |
INSMED Inc
|
104,378 | $11,128,782 |
All Filings in RLAY
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $715,206 | 71,880 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $523,276 | 61,853 | Shares | Sole | 2026-02-17 | |
| 2025-03-31 | $534,624 | 204,055 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,460,540 | 354,500 | Shares | Sole | 2025-02-14 | |
| 2024-06-30 | $687,977 | 105,518 | Shares | Sole | 2024-08-14 | |
| 2022-12-31 | $352,628 | 23,603 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $484,556 | 21,661 | Shares | Sole | 2022-11-14 | |
| 2020-09-30 | $786,765 | 18,473 | Shares | Sole | 2020-11-19 | |
| No filing history on record for this holder in this stock. | ||||||